Literature DB >> 32462945

Chronic Obstructive Pulmonary Disease Prevalence and Associated Factors in a Setting of Well-Controlled HIV, A Cross-Sectional Study.

Alex Kayongo1,2,3, Adaeze C Wosu2,3, Tasmia Naz2, Faith Nassali1,4, Robert Kalyesubula1,4, Bruce Kirenga1,5, Robert A Wise2, Trishul Siddharthan2,3, William Checkley2,3.   

Abstract

In Sub-Saharan Africa, COPD remains prevalent but its association with HIV is not well characterized especially in rural settings. We assessed for COPD prevalence, associated factors and lung function profile among HIV-infected individuals attending ART clinics in rural Nakaseke district of Uganda. We enrolled HIV-positive participants from four HIV treatment centers in rural Uganda. Participants underwent spirometry testing following standard guidelines. We defined COPD as a post-bronchodilator FEV1/FVC ratio less than the fifth percentile of the NHANES III African-American reference. We assessed for factors associated with COPD and lung function profiles using multivariable logistic and linear regression analyses. We analyzed data from 722 HIV-positive participants (mean age 48.0 years, 59.7% women). Over 90% of participants were on ART for a median duration of 4 years (IQR 2-7 years), with a median viral load of 0 copies/mL (IQR 0-0 copies/mL), current and baseline CD4 + T cell count of 478 cells/mm3 (IQR 346-663 cells/mm3) and 335 cells/mm3 (IQR 187-523 cells/mm3) respectively. The prevalence of COPD was 6.22%. COPD was associated with worse respiratory symptoms and health status. History of pulmonary tuberculosis was strongly associated with COPD (adjusted OR = 4.92, 95% CI 1.71 to 14.15, p = 0.003) and reduced lung function. Use of ART, CD4+T cell count and viral load were not associated with COPD or reduced lung function. In conclusion, we report a COPD prevalence of 6.22% in HIV-infected individuals in rural Uganda. Pulmonary tuberculosis remains the strongest predictor of COPD risk and reduced lung function in well-controlled HIV.

Entities:  

Keywords:  AIDS; COPD; HIV; HIV-associated COPD

Year:  2020        PMID: 32462945      PMCID: PMC8126339          DOI: 10.1080/15412555.2020.1769583

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  30 in total

1.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

2.  Standardisation of spirometry.

Authors:  M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger
Journal:  Eur Respir J       Date:  2005-08       Impact factor: 16.671

3.  Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era.

Authors:  Matthew R Gingo; M Patricia George; Cathy J Kessinger; Lorrie Lucht; Barbara Rissler; Renee Weinman; William A Slivka; Deborah K McMahon; Sally E Wenzel; Frank C Sciurba; Alison Morris
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

4.  Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.

Authors:  Ken M Kunisaki; Dennis E Niewoehner; Gary Collins; Bitten Aagaard; Nafisah B Atako; Elzbieta Bakowska; Amanda Clarke; Giulio Maria Corbelli; Ernest Ekong; Sean Emery; Elizabeth B Finley; Eric Florence; Rosa M Infante; Cissy M Kityo; Juan Sierra Madero; Daniel E Nixon; Ellen Tedaldi; Jørgen Vestbo; Robin Wood; John E Connett
Journal:  Lancet Respir Med       Date:  2016-10-20       Impact factor: 30.700

5.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.

Authors:  Jeffrey S A Stringer; Isaac Zulu; Jens Levy; Elizabeth M Stringer; Albert Mwango; Benjamin H Chi; Vilepe Mtonga; Stewart Reid; Ronald A Cantrell; Marc Bulterys; Michael S Saag; Richard G Marlink; Alwyn Mwinga; Tedd V Ellerbrock; Moses Sinkala
Journal:  JAMA       Date:  2006-08-16       Impact factor: 56.272

Review 6.  TB meets COPD: An emerging global co-morbidity in human lung disease.

Authors:  Ronan F O'Toole; Shakti D Shukla; E Haydn Walters
Journal:  Tuberculosis (Edinb)       Date:  2015-09-02       Impact factor: 3.131

7.  HIV Associated Chronic Obstructive Pulmonary Disease in Nigeria.

Authors:  Maxwell O Akanbi; Babafemi O Taiwo; Chad J Achenbach; Obianuju B Ozoh; Daniel O Obaseki; Halima Sule; Oche O Agbaji; Christiana O Ukoli
Journal:  J AIDS Clin Res       Date:  2015-05

8.  HIV infection is associated with diffusing capacity impairment in women.

Authors:  Meghan E Fitzpatrick; Matthew R Gingo; Cathy Kessinger; Lorrie Lucht; Eric Kleerup; Ruth M Greenblatt; David Claman; Claudia Ponath; Serena Fong; Laurence Huang; Alison Morris
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

9.  Socioeconomic status and COPD among low- and middle-income countries.

Authors:  Matthew Grigsby; Trishul Siddharthan; Muhammad Ah Chowdhury; Ali Siddiquee; Adolfo Rubinstein; Edgardo Sobrino; J Jaime Miranda; Antonio Bernabe-Ortiz; Dewan Alam; William Checkley
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-10-05

10.  Adult life expectancy trends in the era of antiretroviral treatment in rural Uganda (1991-2012).

Authors:  Gershim Asiki; Georges Reniers; Robert Newton; Kathy Baisley; Jessica Nakiyingi-Miiro; Emma Slaymaker; Ivan Kasamba; Janet Seeley; Jim Todd; Pontiano Kaleebu; Anatoli Kamali
Journal:  AIDS       Date:  2016-01-28       Impact factor: 4.177

View more
  4 in total

Review 1.  Chronic obstructive pulmonary disease in HIV.

Authors:  Katerina Byanova; Ken M Kunisaki; Joshua Vasquez; Laurence Huang
Journal:  Expert Rev Respir Med       Date:  2020-11-23       Impact factor: 3.772

2.  Symptoms and functional limitations related to respiratory health and carbon monoxide poisoning in Tanzania: a cross sectional study.

Authors:  Thomas Zoller; Elirehema H Mfinanga; Tresphory B Zumba; Peter J Asilia; Edwin M Mutabazi; David Wimmersberger; Francis Mhimbira; Frederick Haraka; Klaus Reither
Journal:  Environ Health       Date:  2022-04-02       Impact factor: 5.984

Review 3.  Mycobacterium tuberculosis and Pulmonary Rehabilitation: From Novel Pharmacotherapeutic Approaches to Management of Post-Tuberculosis Sequelae.

Authors:  Andreea-Daniela Meca; Liliana Mititelu-Tarțău; Maria Bogdan; Lorena Anda Dijmarescu; Ana-Maria Pelin; Liliana Georgeta Foia
Journal:  J Pers Med       Date:  2022-04-02

4.  Chronic obstructive pulmonary disease prevalence and associated factors in an urban HIV clinic in a low income country.

Authors:  Ahmed Ddungu; Fred C Semitala; Barbara Castelnuovo; Christine Sekaggya-Wiltshire; William Worodria; Bruce J Kirenga
Journal:  PLoS One       Date:  2021-08-13       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.